LIVE
VEEV
Veeva Systems Inc. · Technology - Life Sciences SaaS
$153.30
-6.13% this month
VERSUS
⟷
COMPARE
IQV
IQVIA Holdings, Inc. · Healthcare - Life Sciences Data & Services
$167.77
-3.12% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
VEEV
1
IQV
3
Comparison scoreboard
IQV LEADS 3/5AI Score
VEEV 50.3
IQV ✓51.2
1Y Return
VEEV -45.53%
IQV ✓+8.87%
Fwd P/E
VEEV 15.28
IQV ✓12.78
Target Up.
VEEV ✓+60.13%
IQV +25.07%
Op. Margin
VEEV N/A
IQV 13.61%
Metrics last refreshed: 6/20/2026
Quick take
VEEV vs IQV Stock Comparison: AI Score, Valuation, Performance and Upside
VEEV (Veeva Systems) and IQV (IQVIA) both serve the life sciences industry but from different angles — Veeva is a pure SaaS platform company providing commercial and clinical cloud software to pharma companies, while IQVIA is a diversified life sciences data, analytics, and CRO services company with vast proprietary health data assets and clinical research execution capabilities. Veeva is the cloud software play; IQVIA is the data and services play.
VEEV vs IQV is pharma cloud platform specialist (Veeva's deeply embedded CRM and clinical cloud software driving pharma commercial and regulatory workflow with high switching costs) versus life sciences data and services giant (IQVIA's unparalleled health data assets and global CRO capabilities creating a moat through data scale and clinical trial execution expertise) — cloud software SaaS model versus data and services model in life sciences.
Live analysis · updated 6/20/2026
IQV holds the edge across 3 of 5 key metrics in this comparison. IQV leads on both 1-year return (+8.87%) and forward P/E (12.78x vs 15.28x for VEEV), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for VEEV (+60.13%) than for IQV (+25.07%).
Normalized 1Y performance
VEEV
IQV
Recent returns
VEEV
IQV
Analyst price targets & sentiment
VEEV · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.9/5.0)
Price target range
analyst low$165.00
analyst high$350.00
analyst mean$245.48
current price$153.30
+60.1% upside to analyst mean
IQV · 19 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.7/5.0)
Price target range
analyst low$160.00
analyst high$268.00
analyst mean$226.95
current price$167.77
+25.1% upside to analyst mean
Who should consider this stock?
VEEV may suit investors who:
- →Want a high-quality life sciences SaaS company with deep pharma workflow embedding and high net retention — Veeva's software is mission-critical for pharma commercial and regulatory operations, creating durable recurring revenue
- →Value Veeva's Vault platform as a long-term growth engine expanding across clinical operations — as pharma companies standardize R&D workflows on Vault, Veeva's revenue per customer grows
- →Prefer Veeva's pure-play software model with high margins and capital-light growth versus IQVIA's more complex mix of software, services, and data
IQV may suit investors who:
- →Want life sciences data assets with near-monopoly characteristics — IQVIA's health data scale (billions of de-identified patient records globally) is a competitive moat that pharmaceutical companies are structurally dependent on for drug launch analytics
- →Value IQVIA's CRO services as mission-critical for pharmaceutical drug development — clinical trial management by a reliable global CRO is essential for drug approval timelines, creating long-term client relationships
- →See IQVIA's technology investment in its CRO as creating a differentiated, tech-enabled services model that earns premium pricing versus pure-service CRO competitors
Performance & AI score
| Metric | VEEV | IQV |
|---|---|---|
| AI score | 50.3 | 51.2 |
| AI rank | #454 | #391 |
| Latest close | $153.30 | $167.77 |
| 1M return | -6.13% | -3.12% |
| 6M return | -28.85% | -24.23% |
| 1Y return | -45.53% | +8.87% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VEEV | IQV |
|---|---|---|
| 1Y ago | $5.45K (-45.5%) started 2025-06-18 | $10.85K (+8.5%) started 2025-06-18 |
| 5Y ago | $5K (-50.0%) started 2021-06-18 | $6.89K (-31.1%) started 2021-06-21 |
| 10Y ago | $44.71K (+347.1%) started 2016-06-20 | $26.34K (+163.4%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | VEEV | IQV |
|---|---|---|
| Market cap | $24.9B | $30.29B |
| Trailing P/E | 27.18 | 22.51 |
| Forward P/E | 15.28 | 12.78 |
| Price/Sales | 7.50 | 1.70 |
| EV/Revenue | 5.82 | 2.68 |
| Analyst target | $245.48 | $226.95 |
| Target upside | +60.13% | +25.07% |
Growth, profitability & risk
| Metric | VEEV | IQV |
|---|---|---|
| Revenue growth | 16.30% | 8.40% |
| Earnings growth | 14.60% | 15.00% |
| EPS growth | +14.60% | +15.00% |
| FCF margin | +37.95% | +12.97% |
| Operating margin | N/A | 13.61% |
| Profit margin | 28.37% | 8.33% |
| ROIC proxy | 13.93% | 22.49% |
| Return on equity | 13.93% | 22.49% |
| Dividend yield | 0.00% | N/A |
| Beta | 0.95 | 1.22 |
| Debt/equity | 1.41 | 255.43 |
| Current ratio | 4.74 | 0.75 |
| Quick ratio | 4.67 | 0.66 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
VEEV max drawdown50.55%
IQV max drawdown35.87%
VEEV max wkly drop16.81%
IQV max wkly drop23.20%
5Y risk snapshot
VEEV max drawdown55.69%
IQV max drawdown51.52%
VEEV max wkly drop21.64%
IQV max wkly drop23.20%
10Y risk snapshot
VEEV max drawdown55.69%
IQV max drawdown51.52%
VEEV max wkly drop21.64%
IQV max wkly drop28.34%
Performance metrics by period
| Period | Metric | VEEV | IQV |
|---|---|---|---|
| 1Y | Growth | -45.53% | +8.51% |
| CAGR | -45.55% | +8.52% | |
| Sharpe ratio | -1.63 | 0.29 | |
| Max drawdown | 50.55% | 35.87% | |
| Max daily drop | 9.77% | 11.88% | |
| Max wkly drop | 16.81% | 23.20% | |
| 5Y | Growth | -50.02% | -31.09% |
| CAGR | -12.95% | -7.19% | |
| Sharpe ratio | -0.30 | -0.19 | |
| Max drawdown | 55.69% | 51.52% | |
| Max daily drop | 16.24% | 11.88% | |
| Max wkly drop | 21.64% | 23.20% | |
| 10Y | Growth | +347.07% | +163.42% |
| CAGR | +16.17% | +10.18% | |
| Sharpe ratio | 0.47 | 0.32 | |
| Max drawdown | 55.69% | 51.52% | |
| Max daily drop | 16.24% | 16.54% | |
| Max wkly drop | 21.64% | 28.34% |
Business comparison
| Category | VEEV | IQV |
|---|---|---|
| Company | Veeva Systems Inc. | IQVIA Holdings, Inc. |
| Sector | Technology - Life Sciences SaaS | Healthcare |
| Industry | N/A | Diagnostics & Research |
| Core business | Veeva Systems is a cloud software company exclusively serving the life sciences industry — providing CRM (Veeva CRM for pharma salesforces), clinical operations software (Veeva Vault for clinical data, regulatory submissions, quality management), data and analytics solutions, and the Veeva Network (master data management for healthcare professional data). Veeva has positioned itself as the industry-specific cloud suite for pharmaceutical, biotech, and medical device companies. | IQVIA is a global life sciences data, technology, and services company — providing real-world health data analytics (covering billions of patient records across 100+ countries), clinical research services (CRO), technology solutions for drug commercialization, regulatory compliance, and healthcare intelligence. IQVIA's data assets (pharmacy claims, EMR data, prescription data) are among the most comprehensive in the world and are used by pharmaceutical companies for drug launch analytics, market research, and clinical trial site selection. |
| Investor focus | Investors track Veeva's Vault platform growth (the clinical and regulatory cloud that is growing faster than the legacy CRM business), commercial cloud ARR expansion, net revenue retention, and the long-term competitive threat from Salesforce (Veeva was originally built on Salesforce and is migrating to its own CRM platform) and data cloud competitors. | Investors track IQVIA's three segments — TAS (Technology & Analytics Solutions), R&DS (Research & Development Solutions, the CRO business), and Contract Sales & Medical Solutions — revenue growth and margin, CRO backlog (future revenue visibility), real-world data monetization, and technology adoption by life sciences customers transitioning from traditional CRO services to technology-enabled clinical research. |
VEEV strengths
- →Dominant pharma CRM and regulatory cloud position — Veeva's software is deeply embedded in pharmaceutical commercial operations and regulatory workflows; replacing Veeva would require retraining thousands of pharma sales reps and migrating years of regulatory data
- →Vault platform expanding across clinical development workflows — Veeva's Vault products cover clinical data management, regulatory submissions, quality management, and safety; life sciences companies increasingly standardize on Vault for end-to-end clinical operations
- →Industry-exclusive focus creates deep domain expertise — Veeva only serves life sciences; its software is configured with pharma-specific workflows, regulatory requirements (FDA, EMA), and data standards that generic cloud platforms cannot match out of the box
IQV strengths
- →Unparalleled real-world health data assets — IQVIA's proprietary dataset of de-identified patient records, prescription claims, and longitudinal health data from billions of patients globally is a competitive moat that is difficult to replicate; pharmaceutical companies rely on this data for drug launch analytics, patient finding, and real-world evidence
- →CRO scale and global footprint — IQVIA's clinical research organization is one of the world's largest, managing Phase I-IV clinical trials across 100+ countries with established regulatory expertise and site networks
- →Technology integration into CRO services — IQVIA has invested in technology platforms that improve clinical trial efficiency (patient matching to trials, remote monitoring, decentralized trial capabilities), differentiating its CRO from pure-service competitors
Risks to watch — VEEV
- →Salesforce competitive risk in CRM — Veeva was built on Salesforce and announced it would move off Salesforce's platform; Salesforce is now building its own life sciences CRM to compete with Veeva directly, leveraging its existing data from pharma customers
- →Clinical data platform competition from IQVIA, Medidata (Dassault), and Oracle Health Sciences — the clinical trial data management market is contested by multiple large players with different technology approaches
- →Biotech funding cycle sensitivity — Veeva's smaller biotech customer segment is sensitive to biotech funding; when venture capital and IPO markets are weak, small biotech companies defer software spending
Risks to watch — IQV
- →CRO market competition from ICON, PPD (Thermo Fisher), Covance (Labcorp), and Syneos Health — the contract research market is competitive with multiple large global CROs competing on price, therapy area expertise, and technology
- →Data privacy regulations limiting health data use — health data regulations (HIPAA in the U.S., GDPR in Europe) constrain how patient data can be collected, processed, and used; regulatory tightening could limit IQVIA's data monetization
- →Pharmaceutical R&D spending cycles — clinical trial volumes and CRO revenue are tied to pharmaceutical R&D investment; when large pharma companies merge, restructure, or cut pipelines, CRO backlog can decline
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →